---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-23-004181"
form_type: "8-K"
ticker: "VNOV"
cik: "0001699709"
company_name: "VitaNova Life Sciences Corp"
filed_at: "2023-06-15T23:59:59+00:00"
generated_at: "2026-06-14T00:21:07.784039+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Xianchang Ma acquires 86.3% of Yijia Group; appointed CEO, President, CFO and Director

## Summary
- Barry Sytner sold 5,066,250 shares (86.3% of outstanding) to Xianchang Ma for $470,562 on June 14, 2023.
- Sytner resigned as CEO, President, CFO, and Director; Ma appointed to all those roles effective June 14, 2023.
- Xianchang Ma, age 48, is CEO and director of Tengjun Biotechnology Corp; founded Jinan Tengiun Biological Technology in 2014.
- Purchase price paid from Ma's personal funds; agreement included escrow and conditions such as filing of Form 10-K.

## SEC filing metadata
- accession: 0001683168-23-004181
- form_type: 8-K
- ticker: VNOV
- cik: 0001699709
- company_name: VitaNova Life Sciences Corp
- filed_at: 2023-06-15T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.01, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1699709/000168316823004181/0001683168-23-004181-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1699709/000168316823004181/yijia_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-23-004181
- JSON: https://secwatch.observer/filing/0001683168-23-004181.json
- Plain text: https://secwatch.observer/filing/0001683168-23-004181.txt

## Key facts
- Executive change
  Xianchang Ma was appointed as President at VitaNova Life Sciences Corp.
  - Action: appointed
  - Role: President
  source text: On June 14, 2023, the sole Director of the Company, Mr Sytner, resolved to step down from his positions as Chief Executive Officer, President, Chief Financial Officer and Director of the Company, and for Mr. Xianchang Ma to be appointed as the Chief Executive Officer, President, Chief Financial Officer and Director of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1699709/000168316823004181/0001683168-23-004181-index.htm
- Executive change
  Barry Sytner resigned as Chief Executive Officer at VitaNova Life Sciences Corp.
  - Action: resigned
  - Role: Chief Executive Officer
  source text: On June 14, 2023, the sole Director of the Company, Mr Sytner, resolved to step down from his positions as Chief Executive Officer, President, Chief Financial Officer and Director of the Company, and for Mr. Xianchang Ma to be appointed as the Chief Executive Officer, President, Chief Financial Officer and Director of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1699709/000168316823004181/0001683168-23-004181-index.htm
- Executive change
  Barry Sytner resigned as President at VitaNova Life Sciences Corp.
  - Action: resigned
  - Role: President
  source text: On June 14, 2023, the sole Director of the Company, Mr Sytner, resolved to step down from his positions as Chief Executive Officer, President, Chief Financial Officer and Director of the Company, and for Mr. Xianchang Ma to be appointed as the Chief Executive Officer, President, Chief Financial Officer and Director of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1699709/000168316823004181/0001683168-23-004181-index.htm
- Executive change
  Barry Sytner resigned as Chief Financial Officer at VitaNova Life Sciences Corp.
  - Action: resigned
  - Role: Chief Financial Officer
  source text: On June 14, 2023, the sole Director of the Company, Mr Sytner, resolved to step down from his positions as Chief Executive Officer, President, Chief Financial Officer and Director of the Company, and for Mr. Xianchang Ma to be appointed as the Chief Executive Officer, President, Chief Financial Officer and Director of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1699709/000168316823004181/0001683168-23-004181-index.htm
- Executive change
  Xianchang Ma was appointed as Director at VitaNova Life Sciences Corp.
  - Action: appointed
  - Role: Director
  source text: On June 14, 2023, the sole Director of the Company, Mr Sytner, resolved to step down from his positions as Chief Executive Officer, President, Chief Financial Officer and Director of the Company, and for Mr. Xianchang Ma to be appointed as the Chief Executive Officer, President, Chief Financial Officer and Director of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1699709/000168316823004181/0001683168-23-004181-index.htm
- Executive change
  Xianchang Ma was appointed as Chief Financial Officer at VitaNova Life Sciences Corp.
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On June 14, 2023, the sole Director of the Company, Mr Sytner, resolved to step down from his positions as Chief Executive Officer, President, Chief Financial Officer and Director of the Company, and for Mr. Xianchang Ma to be appointed as the Chief Executive Officer, President, Chief Financial Officer and Director of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1699709/000168316823004181/0001683168-23-004181-index.htm
- Executive change
  Barry Sytner resigned as Director at VitaNova Life Sciences Corp.
  - Action: resigned
  - Role: Director
  source text: On June 14, 2023, the sole Director of the Company, Mr Sytner, resolved to step down from his positions as Chief Executive Officer, President, Chief Financial Officer and Director of the Company, and for Mr. Xianchang Ma to be appointed as the Chief Executive Officer, President, Chief Financial Officer and Director of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1699709/000168316823004181/0001683168-23-004181-index.htm
- Executive change
  Xianchang Ma was appointed as Chief Executive Officer at VitaNova Life Sciences Corp.
  - Action: appointed
  - Role: Chief Executive Officer
  source text: On June 14, 2023, the sole Director of the Company, Mr Sytner, resolved to step down from his positions as Chief Executive Officer, President, Chief Financial Officer and Director of the Company, and for Mr. Xianchang Ma to be appointed as the Chief Executive Officer, President, Chief Financial Officer and Director of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1699709/000168316823004181/0001683168-23-004181-index.htm
- M&A Transactions
  VitaNova Life Sciences Corp underwent a change of control involving Xianchang Ma for $470,562 (closed 2023-06-14).
  - Action: change of control
  - Counterparty: Xianchang Ma
  - Consideration: $470,562
  - Closing: 2023-06-14
  source text: of common stock of the Company to Mr. Ma, constituting approximately 86.3% of the issued and outstanding shares of the Company as of May 2, 2023, for a total consideration of $470,562, derived from the purchaser’s personal funds. The Securities Purchase Agreement was closed on June 14, 2023. Following the closing, Mr. Ma acquired a beneficial interest in
  evidence_url: https://www.sec.gov/Archives/edgar/data/1699709/000168316823004181/0001683168-23-004181-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.